Literature DB >> 26767714

Can admission serum cystatin C level be an early marker subclinical acute kidney injury in critical care patients?

Ümmügülsüm Gaygısız1, Müge Aydoğdu1, Melike Badoğlu1, Nazlıhan Boyacı1, Zuhal Güllü1, Gül Gürsel1.   

Abstract

BACKGROUND: In critical care patients, the diagnosis of subclinical acute kidney injury (AKI) might be difficult with measurements of serum creatinine and estimated glomerular filtration rate (eGFR). Their 'sensitive kidneys' can easily be affected from sepsis, underlying diseases, medications and volume status and if they can be detected earlier, some preventive measures might be taken. In this study we aimed to determine whether admission serum cystatin C (sCys-C) and other clinical parameters can identify subclinical AKI in medical intensive care unit (ICU) patients with normal creatinine-based eGFR at admission.
METHODS: A prospective cohort study, performed in an adult ICU of a university hospital between January 2008 and March 2013. The blood samples were obtained within the first 24-48 hours of admission and sCys-C levels were analyzed with particle-enhanced immunonephelometric assay. AKI development was assessed according to RIFLE criteria. The cutoff value of sCys-C for the prediction of AKI was determined with receiver operating characteristic (ROC) curve analysis.
RESULTS: A total of 72 patients were included in the study and 19 (26%) of them developed AKI. Among the patients with AKI admission sCys-C levels were significantly higher when compared with non-AKI patients (1.06 ± 0.29 vs. 0.89 ± 0.28 respectively, p = 0.026). With ROC curve analysis, the threshold level for sCys-C was 0.94 mg/L with 63% sensitivity and 66% specificity [AUC: 0.67, p = 0.026]. With logistic regression analysis 'high sCys-C levels at admission' (OR = 4.73; 95%CI 1.03-21.5, p = 0.044) was found as one of the independent variables for the prediction of AKI development, in addition to 'being intubated before ICU admission' (OR = 10.2; 95%CI 1.72-60.4, p = 0.01) and 'hypotension during ICU follow-up' (OR = 12.3; 95%CI 2.5-60.1, p = 0.002).
CONCLUSION: In this cohort of patients, a high sCys-C level at admission was found to be a predictor of subclinical AKI arising during their ICU stay. If supported with further studies, it might be used to provide more accurate and earlier knowledge about renal dysfunction and to take appropriate preventive measures.

Entities:  

Keywords:  Serum cystatin C; acute kidney injury; glomerular filtration rate; intensive care unit; serum creatinine

Mesh:

Substances:

Year:  2016        PMID: 26767714     DOI: 10.3109/00365513.2015.1126854

Source DB:  PubMed          Journal:  Scand J Clin Lab Invest        ISSN: 0036-5513            Impact factor:   1.713


  9 in total

1.  Serum Cystatin C Level Monitoring for Intervention Opportunity of CBP in Children with Severe Sepsis.

Authors:  Weikai Wang; Yi Qiang; Zhongbin Tao; Baowang Yang; Bin Yan; Xilong Chen; Ruifeng Xu
Journal:  Evid Based Complement Alternat Med       Date:  2022-06-29       Impact factor: 2.650

Review 2.  Biomarkers in critical illness: have we made progress?

Authors:  Patrick M Honore; Rita Jacobs; Inne Hendrickx; Elisabeth De Waele; Viola Van Gorp; Olivier Joannes-Boyau; Jouke De Regt; Willem Boer; Herbert D Spapen
Journal:  Int J Nephrol Renovasc Dis       Date:  2016-10-17

3.  Predictive value of serum cystatin C for acute kidney injury in adults: a meta-analysis of prospective cohort trials.

Authors:  Zhenzhu Yong; Xiaohua Pei; Bei Zhu; Haichuan Yuan; Weihong Zhao
Journal:  Sci Rep       Date:  2017-01-23       Impact factor: 4.379

4.  Clinical significance of novel biomarker NGAL in early diagnosis of acute renal injury.

Authors:  Jinghua Zhang; Jianle Han; Jinrui Liu; Bing Liang; Xiaobo Wang; Changan Wang
Journal:  Exp Ther Med       Date:  2017-09-20       Impact factor: 2.447

5.  The diagnostic value of serum creatinine and cystatin c in evaluating glomerular filtration rate in patients with chronic kidney disease: a systematic literature review and meta-analysis.

Authors:  Xilian Qiu; Chunyong Liu; Yuqiu Ye; Hongyong Liu; Huiqun Li; Yanbing Chen; Yongmei Fu; Zhenjie Liu; Xianzhang Huang; Yunqiang Zhang; Xueyuan Liao; Wenbo Zhao; Xun Liu
Journal:  Oncotarget       Date:  2017-08-16

6.  Early prediction of COVID-19-associated acute kidney injury: Are serum NGAL and serum Cystatin C levels better than serum creatinine?

Authors:  Naomi Pode Shakked; Maria Helena Santos de Oliveira; Isaac Cheruiyot; Justin L Benoit; Mario Plebani; Giuseppe Lippi; Stefanie W Benoit; Brandon Michael Henry
Journal:  Clin Biochem       Date:  2022-01-31       Impact factor: 3.625

Review 7.  Advances in the study of subclinical AKI biomarkers.

Authors:  Chenchen Zou; Chentong Wang; Lin Lu
Journal:  Front Physiol       Date:  2022-08-24       Impact factor: 4.755

8.  NGAL, albumin and cystatin C during cisplatin therapy.

Authors:  B Florova; D Rajdl; J Racek; O Fiala; V M Matejka; L Trefil
Journal:  Physiol Res       Date:  2020-03-23       Impact factor: 1.881

Review 9.  Time-dependent changes in kidney injury biomarkers in patients receiving multiple cycles of cisplatin chemotherapy.

Authors:  Blessy George; Xia Wen; Nickie Mercke; Madeleine Gomez; Cindy O'Bryant; Daniel W Bowles; Yichun Hu; Susan L Hogan; Melanie S Joy; Lauren M Aleksunes
Journal:  Toxicol Rep       Date:  2020-04-22
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.